Forbion

Funding rounds backed by Forbion.

Export CSV
Funding disclosed in full
$620M
Median round
$115M
Rounds in calculation
5
5 rounds
LatestLargest
Funding rounds with company descriptions, amounts, stages and announcement dates
CompanyRoundMarketInvestorsAnnouncedDetails
RQ Bio

Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients

$115MSeries ABiotechUnited Kingdom
8 participantsEQT Life SciencesForbionFrazier Life SciencesLifeArcMonographOxford Science EnterprisesOxford University InnovationWellington Management
CellCentric

Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma

$220MSeries DBiotechUnited Kingdom
9 participantsAmerican Cancer Society BrightEdgeAvego BioScience CapitalFidelity Management & Research CompanyForbionHBM HealthcarePfizerRA Capital ManagementSofinnova PartnersVenrock Healthcare Capital Partners
Slate Medicines

Advancing next-generation therapeutics for migraine and other headache disorders

$130MSeries ABiotechUnited States
3 participantsForbionForesite CapitalRA Capital Management
Altesa BioSciences

Develops treatments for chronic lung diseases, focusing on viral respiratory infections

$75MSeries BBiotechUnited States
5 participantsAtlantic PartnersForbionMedicxiPitangoSanofi
Corsera Health

Develops preventive RNAi medicines for cardiovascular disease prediction and prevention

$80MSeries AHealthtechUnited States
2 participantsForbionPopulation Health Partners